Impact of post-challenge hyperglycemia on clinical outcomes in japanese patients with stable angina undergoing percutaneous coronary intervention

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Kuramitsu, Shoichi ^a   Yokoi, Hiroyoshi ^a   Domei, Takenori ^a   Nomura, Akihiro ^a   Watanabe, Hirotoshi ^a   Yamaji, Kyohei ^a   Soga, Yoshimitsu ^a   Arita, Takeshi ^a   Kondo, Katsuhiro ^a   Shirai, Shinichi ^a   Ando, Kenji ^a   Sakai, Koyu ^a   Iwabuchi, Masashi ^a   Nosaka, Hedeyuki ^a   Nobuyoshi, Masakiyo ^a  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

Author keywords

Coronary artery disease; Diabetes mellitus; Percutaneous coronary intervention; Post challenge hyperglycemia; Stable angina

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; THIENOPYRIDINE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN TREATMENT; JAPANESE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; STABLE ANGINA PECTORIS; ANGINA, STABLE; COMPLICATION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

AGED; ANGINA, STABLE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84877032796     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-74     Document Type: Article

References (45)

1. National Institute of Diabetes and Digestive and Kidney Diseases National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005 2005, Bethesda, MD: US Department of Health and Human Services, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
2. The DECODE study group Glucose tolerance and cardiovascular mortality: comparison of fasting and 2 h diagnostic criteria. Arch Intern Med 2001, 161:397-405. 10.1001/archinte.161.3.397, 11176766, The DECODE study group.
3. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003, 34:2349-2354. 10.1161/01.STR.0000090348.52943.A2, 12958323.
4. Saito I. Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. Circ J 2012, 76:1066-1073. 10.1253/circj.CJ-11-1519, 22453006.
5. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J 1986, 112:825-836. 10.1016/0002-8703(86)90481-3, 3532744.
6. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study. Circulation 2007, 116:151-157. 10.1161/CIRCULATIONAHA.106.685628, 17576864.
7. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000, 101:975-980. 10.1161/01.CIR.101.9.975, 10704163.
8. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924. 10.2337/diacare.22.6.920, 10372242.
9. Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, Iwamoto Y, Tajima N, International Diabetes Epidemiology Group; DECODA Study Group Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000, 43:1470-1475. 10.1007/s001250051557, 11151755, International Diabetes Epidemiology Group; DECODA Study Group.
10. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004, 164:2147-2155. 10.1001/archinte.164.19.2147, 15505129.
11. Niskanen L, Turpeinen A, Penttila I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 1998, 21:1861-1869. 10.2337/diacare.21.11.1861, 9802734.
12. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359:2140-2144. 10.1016/S0140-6736(02)09089-X, 12090978.
13. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Ohrvik J. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004, 25:1880-1890. 10.1016/j.ehj.2004.07.027, 15522466.
14. Hu DY, Pan CY, Yu JM. for the China Heart Survey Group. The relationship between coronary artery disease an abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 2006, 27:2573-2579. 10.1093/eurheartj/ehl207, 16984927.
15. ADA Classification of Diabetes mellitus. Diabetes Care 2008, 31:S55-S60. ADA.
16. Sourij H, Saely CH, Schmid F, Zweiker R, Marte T, Wascher TC, Drexel H. Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. Eur Heart J 2010, 31:1583-1590. 10.1093/eurheartj/ehq099, 20436047.
17. Japan Diabetes Clinical Data Management Study Group The status of diabetes control and antidiabetic drug therapy in Japan - A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM1). Diab Res Clin Pract 2006, 73:198-204. Japan Diabetes Clinical Data Management Study Group.
18. Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653. 10.1161/CIRCULATIONAHA.107.187397, 17951284, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction.
19. Tamita K, Katayama M, Takagi T, Akasaka T, Yamamuro A, Kaji S, Morioka S, Kihara Y. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J 2007, 71:834-841. 10.1253/circj.71.834, 17526977.
20. de la Hera JM, Delgado E, Hernández E, García-Ruiz JM, Vegas JM, Avanzas P, Lozano I, Barriales-Villa R, Hevia S, Martín JS, Alvarez F, Morís C. Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention. Eur Hear J 2009, 31:2614-2621.
21. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004, 25:1990-1997. 10.1016/j.ehj.2004.09.021, 15541834.
22. Ning F, Zhang L, Dekker JM, Onat A, Stehouwer CD, Yudkin JS, Laatikainen T, Tuomilehto J, Pyörälä K, Qiao Q, DECODE Finnish and Swedish Study Investigators Development of coronary heart disease and ischemic stroke in relation to fasting and 2-hour plasma glucose levels in the normal range. Cardiovasc Diabetol 2012, 11:76. 10.1186/1475-2840-11-76, 3423058, 22731255, DECODE Finnish and Swedish Study Investigators.
23. Schinner S, Füth R, Kempf K, Martin S, Willenberg HS, Schott M, Dinh W, Scherbaum WA, Lankisch M. A progressive increase in cardiovascular risk assessed by coronary angiography in non-diabetic patients at sub-diabetic glucose levels. Cardiovasc Diabetol 2011, 10:56. 10.1186/1475-2840-10-56, 3142488, 21702911.
24. Henareh L, Agewall S. 2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus. Cardiovasc Diabetol 2012, 11:93. 10.1186/1475-2840-11-93, 3489682, 22873202.
25. Mazurek M, Kowalczyk J, Lenarczyk R, Zielinska T, Sedkowska A, Pruszkowska-Skrzep P, Swiatkowski A, Sredniawa B, Kowalski O, Polonski L, Strojek K, Kalarus Z. The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively. Cardiovasc Diabetol 2012, 11:78. 10.1186/1475-2840-11-78, 3490817, 22741568.
26. Haller H. Postprandial glucose and vascular disease. Diabet Med 1997, 14:S50-S56. 10.1002/(SICI)1096-9136(199708)14:3+3.3.CO;2-T, 9272614.
27. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004, 44:2293-2300. 10.1016/j.jacc.2004.07.060, 15607389.
28. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 2007, 99:6B-14B.
29. Nishimoto Y, Miyazaki Y, Toki Y, Murakami R, Shinoda M, Fukushima A, Kanayama H. Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina. J Am Coll Cardiol 1998, 32:1624-1629. 10.1016/S0735-1097(98)00428-8, 9822088.
30. Osanai H, Kanayama H, Miyazaki Y, Fukushima A, Shinoda M, Ito T. Usefulness of enhanced insulin secretion during an oral glucose tolerance test as a predictor of restenosis after direct percutaneous transluminal coronary angioplasty during acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol 1998, 81:698-701. 10.1016/S0002-9149(97)01021-7, 9527077.
31. Nakamura N, Ueno Y, Tsuchiyama Y, Koike Y, Gohda M, Satani O. Isolated post-challenge hyperglycemia in patients with normal fasting glucose concentration exaggerates neointimal hyperplasia after coronary stent implantation. Circ J 2003, 67:61-67. 10.1253/circj.67.61, 12520154.
32. Lima-Filho MO, Figueiredo GL, Foss-Freitas MC, Foss MC, Marin-Neto JA. Predictors of restenosis after percutaneous coronary intervention using bare-metal stents: a comparison between patients with and without dysglycemia. Braz J Med Biol Res 2010, 43:572-579. 10.1590/S0100-879X2010007500051, 20521015.
33. Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K, Yoshimasa Y, Miyazaki S, DIANA study investigators Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J 2012, 76:712-720. 10.1253/circj.CJ-11-1011, 22240597, DIANA study investigators.
34. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589. 10.1056/NEJMoa0806470, 18784090.
35. Lankisch M, Füth R, Schotes D, Rose B, Lapp H, Rathmann W, Haastert B, Gülker H, Scherbaum WA, Martin S. High prevalence of undiagnosed impaired glucose regulation and diabetes mellitus in patients scheduled for an elective coronary angiography. Clin Res Cardiol 2006, 95:80-87. 10.1007/s00392-006-0328-4, 16598515.
36. de la Hera JM, García-Ruiz JM, Martínez-Camblor P, Martín M, Tellería AL, Corros C, Torres F, Fernández-Cimadevilla OC, Alvarez-Pichel I, Capín E, Avanzas P, Delgado E. Real incidence of diabetes mellitus in a coronary disease population. Am J Cardiol 2013, 11:333-338.
37. de la Hera JM, Delgado E, Martínez-Camblor P, Vegas JM, García-Ruiz JM, Rodriguez-Lambert JL. Oral glucose tolerance test as a tool for patient improvement after percutaneous coronary intervention. Rev Esp Cardiol (Engl Ed) 2012, 65:1054-1056.
38. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2012, 1:S64-S71. American Diabetes Association.
39. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28:88-136.
40. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504. 10.1056/NEJMoa040583, 15007110.
41. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080. 10.1001/jama.291.9.1071, 14996776, REVERSAL Investigators.
42. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M, COSMOS Investigators Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009, 73:2110-2117. 10.1253/circj.CJ-09-0358, 19801853, COSMOS Investigators.
43. Daida H, Takayama T, Hiro T, Yamagishi M, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M, COSMOS Investigators High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Diabetol 2012, 11:87. 10.1186/1475-2840-11-87, 3444370, 22831708, COSMOS Investigators.
44. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P, Nissen SE. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol 2010, 55:2736-2742. 10.1016/j.jacc.2010.01.050, 20538166.
45. Ye Y, Xie H, Zhao X, Zhang S. The oral glucose tolerance test for the diagnosis of diabetes mellitus in patients during acute coronary syndrome hospitalization: a meta-analysis of diagnostic test accuracy. Cardiovasc Diabetol 2012, 11:155. 10.1186/1475-2840-11-155, 3534587, 23270530.